Brokerages expect Humana Inc (NYSE:HUM) to announce $15.90 billion in sales for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Humana’s earnings, with the lowest sales estimate coming in at $15.87 billion and the highest estimate coming in at $15.97 billion. Humana reported sales of $14.26 billion in the same quarter last year, which indicates a positive year over year growth rate of 11.5%. The company is scheduled to announce its next quarterly earnings results on Wednesday, August 7th.

According to Zacks, analysts expect that Humana will report full-year sales of $63.75 billion for the current fiscal year, with estimates ranging from $63.66 billion to $63.85 billion. For the next financial year, analysts anticipate that the company will post sales of $69.24 billion, with estimates ranging from $68.36 billion to $70.57 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Humana.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.30 by $0.18. The firm had revenue of $16.11 billion for the quarter, compared to the consensus estimate of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.36 EPS.

A number of equities research analysts have recently commented on the company. Credit Suisse Group lowered their target price on Humana from $390.00 to $352.00 and set an “outperform” rating on the stock in a research note on Thursday, February 7th. Citigroup lowered their target price on Humana from $397.00 to $362.00 and set a “buy” rating on the stock in a research note on Thursday, February 7th. Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. ValuEngine cut Humana from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Finally, Morgan Stanley set a $331.00 target price on Humana and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company. Humana currently has a consensus rating of “Buy” and an average target price of $337.26.

NYSE HUM opened at $252.83 on Wednesday. The firm has a market cap of $33.06 billion, a PE ratio of 17.38, a price-to-earnings-growth ratio of 1.00 and a beta of 0.85. Humana has a one year low of $225.65 and a one year high of $355.88. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.40.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Thursday, June 27th. Humana’s dividend payout ratio is currently 15.12%.

A number of institutional investors have recently made changes to their positions in HUM. Meridian Wealth Management LLC purchased a new position in Humana during the 1st quarter valued at about $170,000. Allstate Corp grew its holdings in Humana by 0.8% during the 1st quarter. Allstate Corp now owns 10,324 shares of the insurance provider’s stock valued at $2,746,000 after buying an additional 77 shares in the last quarter. Coe Capital Management LLC grew its holdings in Humana by 154.4% during the 1st quarter. Coe Capital Management LLC now owns 4,254 shares of the insurance provider’s stock valued at $1,132,000 after buying an additional 2,582 shares in the last quarter. Nordea Investment Management AB grew its holdings in Humana by 10.4% during the 1st quarter. Nordea Investment Management AB now owns 54,842 shares of the insurance provider’s stock valued at $14,586,000 after buying an additional 5,156 shares in the last quarter. Finally, BlueMountain Capital Management LLC purchased a new position in Humana during the 1st quarter valued at about $6,640,000. Institutional investors and hedge funds own 92.63% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: Trading Stocks – What are percentage gainers?

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.